Health care remains one of the largest and most resilient sectors in the U.S. equity market, but the two ETFs examined here take very different approaches to it. The iShares U.S. Pharmaceuticals ETF (IHE) and the Vanguard Health Care ETF (VHT) do not compete head-to-head so much as they provide distinct exposure profiles within the same broad industry. IHE offers high-conviction, single-industry exposure for investors seeking pure-play access to drug makers. VHT delivers a broad, market-cap-weighted portfolio that captures the full health care spectrum, from pharmaceuticals to insurers and medical technology. Comparing their structures, costs, and risk characteristics helps clarify which version of health care exposure aligns better with a given portfolio.
IHE is a passively managed fund that tracks the Dow Jones U.S. Select Pharmaceuticals Index, a free-float-adjusted, market-capitalization-weighted benchmark focused on U.S. pharmaceutical companies, including prescription drug, over-the-counter, and vaccine makers. The fund holds roughly 57 positions and is highly concentrated, with the top 10 names typically accounting for around 80% of assets. LLY and JNJ each exceed 20% of the portfolio, followed by VTRS, RPRX, ZTS, PFE, MRK, and BMY. Nearly all exposure sits in the pharmaceuticals industry, with negligible cash. Its expense ratio stands at 0.37%. This setup makes IHE a high-conviction, single-theme vehicle whose returns depend heavily on drug-pricing dynamics, patent cycles, and a handful of large weight-loss and immunology franchises. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
VHT is a passively managed fund that tracks the MSCI US Investable Market Health Care 25/50 Index, a benchmark covering large-, mid-, and small-cap U.S. health care stocks under the Global Industry Classification Standard. The fund holds roughly 417 securities, providing exposure across pharmaceuticals, biotechnology, managed care, health care equipment and supplies, and life-science tools. Its largest positions include LLY (around 13%), JNJ, ABBV, MRK, UNH, TMO, AMGN, GILD, ABT, and PFE. Its expense ratio is just 0.09%, among the lowest in the category. The 25/50 methodology caps single-stock weights, preventing any one name from dominating returns and creating a more balanced profile.
Both funds operate in a health care sector shaped by several overlapping forces. Innovation in GLP-1 weight-loss and metabolic therapies has driven outsized gains for a small number of large pharmaceutical franchises, disproportionately benefiting IHE’s concentrated portfolio. At the same time, policy debates around drug pricing, Medicare negotiations, and regulatory scrutiny of pharmacy benefit managers continue to influence sentiment across manufacturers and managed-care providers. Higher-for-longer interest-rate expectations have pressured biotechnology valuations, given their reliance on long-dated cash flows, while defensive, cash-generative large-cap pharma and device makers have shown relative resilience. The broader backdrop features a clear bifurcation: a few high-growth names command premium valuations, while diversified health care companies trade on steadier fundamentals.
Over recent market cycles, IHE’s concentrated exposure to mega-cap pharmaceutical leaders has amplified both upside and downside relative to the wider sector. When GLP-1 and immunology leaders rally, IHE tends to outperform; when single-name earnings disappointments or pricing headlines emerge, its concentration magnifies volatility. VHT, by contrast, has delivered more moderate, diversified performance by blending pharma with managed care, biotech, and medical technology. Its broader holdings and lower beta profile have historically produced smoother positioning, with less sensitivity to any single company’s clinical or regulatory news. On a cost-adjusted basis, VHT’s 0.09% expense ratio compounds favorably over time versus IHE’s 0.37%, a structural edge that persists regardless of short-term sector rotation. Investors seeking tactical, high-beta pharma exposure may prefer IHE, while those prioritizing diversified, low-cost core health care positioning are better served by VHT.
Tickeron’s AI Screener has become a regular part of my process when comparing sector ETFs. The tool lets me quickly filter by industry, holdings concentration, expense ratios, and technical signals, helping confirm whether a concentrated vehicle like IHE or a broader one like VHT better matches current portfolio needs. It surfaces relevant comparisons efficiently without replacing my own analysis.
Based on observable structural factors, Tickeron’s AI would currently favor VHT over IHE. VHT offers a materially lower expense ratio (0.09% versus 0.37%), substantially broader diversification across roughly 417 holdings, and exposure to multiple health care sub-industries that can offset weakness in any single segment. Its 25/50 weighting constraints reduce single-name concentration risk, whereas IHE’s heavy dependence on two mega-cap drug makers concentrates both opportunity and vulnerability. While IHE may outperform during strong, narrow pharma momentum phases, VHT’s combination of cost efficiency, diversification, and balanced risk exposure presents a more consistent, probabilistically favorable structure for broad health care positioning.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day moving average for IHE crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on IHE as a result. In 68 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for IHE just turned positive on October 15, 2026. Looking at past instances where IHE's MACD turned positive, the stock continued to rise in 44 of 51 cases over the following month. The odds of a continued upward trend are 86%.
IHE moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where IHE advanced for three days, in 286 of 343 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 246 of 288 cases where IHE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
The 10-day RSI Indicator for IHE moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 26 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IHE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
IHE broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows